Hengrui Medicine (01276.HK): 9 drugs approved for clinical trials.

Wisdom Financial APP News, Hengrui Medicine (01276.HK) announced that recently, Jiangsu Hengrui Medicine Co., Ltd. and its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd. have received the approval notice for clinical trials of SHR-9839 (sc) for injection, SHR-A2009 for injection, SHR-1826 for injection, HRS-4642 injection solution, Adebely monoclonal antibody injection solution, Rancotuzumab monoclonal antibody for injection, SHR-A2102 for injection, HRS-7058 capsules and HRS-7058 tablets from the National Medical Products Administration, and will soon conduct clinical trials.